Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Lexaria Bioscience Corp.
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
January 11, 2024
From
Lexaria Bioscience Corp.
Via
GlobeNewswire
Tickers
LEXX
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
January 09, 2024
From
Lexaria Bioscience Corp.
Via
GlobeNewswire
Tickers
LEXX
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
November 01, 2023
From
Lexaria Bioscience Corp.
Via
GlobeNewswire
Tickers
LEXX
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
October 31, 2023
From
Lexaria Bioscience Corp.
Via
GlobeNewswire
Tickers
LEXX
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
July 27, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Exposures
Product Safety
Tickers
LEXX
LEXXW
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 26, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Supply Chain
Exposures
Supply Chain
Tickers
LEXX
LEXXW
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
July 14, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
LEXX
LEXXW
Lexaria's Human Nicotine Study Nearing Start Date
July 13, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
LEXX
LEXXW
Cannadips is Expanding Internationally, Leveraging Lexaria's DehydraTECH
July 07, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Signs Manufacturing and License Agreements with BevNology
June 21, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Grants License to AnodGen Bioceuticals
June 08, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
June 06, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Exposures
Product Safety
Tickers
LEXX
LEXXW
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
June 03, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Grants License to Valcon Medical for the European Market
June 02, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Cannabis
Exposures
Cannabis
Tickers
LEXX
LEXXW
Lexaria Announces 2022 Annual Meeting Results
June 01, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
April 21, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Commences Multi-Week Human Clinical Hypertension Study
April 19, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
April 14, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
April 12, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
April 11, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
March 15, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Granted Important New Oral Nicotine Patent
March 08, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
February 02, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Provides Annual Letter From the CEO
January 27, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
December 29, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
December 16, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
December 14, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
December 08, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
November 10, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Tickers
LEXX
LEXXW
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.